文献速递认知障碍与痴呆

阿尔茨海默病血液生物标志物在基层医疗中的应用:生物学与临床效用之间的差距

Blood-Based Biomarkers for Alzheimer Disease in Primary Care: The Gap Between Biology and Clinical Utility.
PubMed 文献 · Neurology · 2026-08-12

本文为个人观点文章,探讨阿尔茨海默病血液生物标志物(BBM)在基层医疗中应用的临床测序、可解释性、路径后果和真实世界效用问题。作者认为负责任实施的主要障碍不仅是分析性能,而是缺乏明确的诊断基础设施,使检测结果具有清晰可操作的角色。在低患病率和临床异质性的基层人群中,临床锚定不足和不稳定的验前概率可能削弱可解释性并促进类别漂移。

要点

  • 基层医疗中AD血液标志物应用应保持选择性、临床锚定和路径依赖。
  • 主要障碍是缺乏明确的诊断基础设施,而非仅分析性能。
  • 低患病率人群中验前概率不稳定可能削弱结果可解释性。

核心结论

  • 在更强证据、更清晰指南和适当服务条件到位前,基层医疗中AD血液标志物使用应保持选择性、临床锚定和路径依赖。

研究设计与样本

  • 本文为个人观点文章,未报告系统检索范围或样本量。

主要发现

  • 在低患病率和临床异质性的基层医疗人群中,临床锚定不足和不稳定的验前概率可能削弱可解释性。
  • 检测结果可能从诊断检测向病例发现或准筛查发生类别漂移。
  • 排除策略的价值取决于阴性结果是否真正改变管理。

临床怎么用

  • 基层医疗使用AD血液标志物应保持选择性、临床锚定和路径依赖。

局限性

  • 本文为个人观点文章,未提供原始研究数据或系统评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Blood-based biomarkers (BBMs) for Alzheimer disease (AD) have accelerated the prospect of earlier and more accessible detection of AD pathology, potentially beyond specialist settings. However, their introduction in primary care raises important questions about clinical sequencing, interpretability, pathway consequences, and real-world utility. In this Personal View, we argue that the main barrier to responsible implementation is not analytical performance alone, but the absence of a sufficiently defined diagnostic infrastructure in which a test result has a clear and actionable role. In low-prevalence and clinically heterogeneous primary care populations, inadequate clinical anchoring and unstable pretest probability may undermine interpretability and promote category drift from diagnostic testing towards case-finding or quasiscreening. Moreover, the value of a rule-out strategy depends on whether a negative result meaningfully changes management. Until stronger evidence, clearer guidance, and appropriate service conditions are in place, primary care use of AD BBMs should remain selective, clinically anchored, and pathway-dependent.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Hazan J, Salemme S, Liu KY, et al. Blood-Based Biomarkers for Alzheimer Disease in Primary Care: The Gap Between Biology and Clinical Utility. Neurology. 2026. PMID: 42585605. doi:10.1212/WNL.0000000000218403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。